This review provides guidance in the decision-making process regarding when to choose a janus kinase [JAK] inhibitor as medical treatment strategy. The focus will be on ulcerative colitis, because the only yet available JAK inhibitor, tofacitinib, has approval for use in ulcerative colitis. The guidance path will include consideration of disease activity, previous treatment, comorbidities, family planning, patient preferences, pharmacology as well as concurrent chronic inflammatory diseases or extraintestinal manifestations. The suggested guidance path illustrates our daily difficulties in the decision-making process regarding best choice for the individual patient. However if predictive biomarkers are lacking, the named criteria can be applied to any other strategy and hence provide support in daily practice.

中文翻译：

---

Janus激酶抑制剂在炎症性肠病的新治疗范例中。

这篇综述为何时选择贾努斯激酶[JAK]抑制剂作为药物治疗策略提供了决策指导。重点将放在溃疡性结肠炎上，因为唯一可用的JAK抑制剂托法替尼已获批准用于溃疡性结肠炎。指导路径将包括疾病活动，先前的治疗，合并症，计划生育，患者喜好，药理学以及并发的慢性​​炎症性疾病或肠外表现的考虑。建议的指导路径说明了我们在决策过程中每天面临的有关个别患者最佳选择的困难。但是，如果缺少预测性生物标志物，则可以将命名标准应用于任何其他策略，从而在日常实践中提供支持。